Canada Markets open in 7 hrs 37 mins

PsyBio Therapeutics Corp. (PSYBF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1582+0.0058 (+3.81%)
At close: 03:33PM EST
Full screen
Loading interactive chart...
  • CNW Group

    PsyBio Therapeutics to Present at the H.C. Wainwright Bioconnect Conference

    PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focusing on discovering and developing new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today announced that Evan Levine, Chief Executive Officer and Chairman, will present at the H.C. Wainwright Bioconnect Conference.

  • CNW Group

    PsyBio Therapeutics Establishes Research and Development Laboratory to Facilitate Portfolio Development Progress

    PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company developing new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today announced that it has expanded its ongoing relationship with Miami University in Oxford, Ohio ("Miami University") by leasing dedicated research and development ("R&D") laboratory space.

  • CNW Group

    PsyBio Therapeutics Successfully Completes First Pre-IND Meeting with the United States Food and Drug Administration

    PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused upon discovery and development of new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today announced the successful completion of its initial pre-Investigational New Drug ("IND") application meeting with the United States Food and Drug Administration ("FDA") as part of the regulatory submission process.